Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

111
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
111
Bioequivalence: Overview01:16

Bioequivalence: Overview

1.4K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.4K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

60
Body:Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug...
60
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

63
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
63
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

75
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
75
Issues And Trends In Healthcare Delivery System01:29

Issues And Trends In Healthcare Delivery System

6.0K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitral Regurgitation in Female Patients: Sex Differences and Disparities.

Journal of the Society for Cardiovascular Angiography & Interventions·2024
Same author

Practical Considerations for Integrating Biosimilars Into Clinical Practice.

Journal of the advanced practitioner in oncology·2021
Same author

Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?

Journal of the advanced practitioner in oncology·2021
Same author

Determination of the Fair Market Value of Oncology Advanced Practitioners.

Journal of the advanced practitioner in oncology·2021
Same author

Oncology Advanced Practitioners and Breast Cancer Prevention.

Journal of the advanced practitioner in oncology·2021
Same author

Accelerated Venovenous Hemofiltration as a Transitional Renal Replacement Therapy in the Intensive Care Unit.

American journal of nephrology·2020
Same journal

Retrospective Characterization of Specialized Palliative Care in Patients With Gliomas.

Journal of the advanced practitioner in oncology·2026
Same journal

Distress Screening in a Cancer Survivorship Clinic: Impact on Psychosocial Referrals.

Journal of the advanced practitioner in oncology·2026
Same journal

Building Bridges: The Impact of Medical Science Liaison and Advanced Practice Provider Collaborations.

Journal of the advanced practitioner in oncology·2026
Same journal

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy.

Journal of the advanced practitioner in oncology·2026
Same journal

Colorectal Cancer Treatment During Pregnancy.

Journal of the advanced practitioner in oncology·2026
Same journal

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma.

Journal of the advanced practitioner in oncology·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K

Challenges of Integrating Biosimilars Into Clinical Practice.

Kate Jeffers1, Megan May2, Wendy H Vogel3

  • 1UCHealth Memorial Hospital, Colorado Springs, Colorado.

Journal of the Advanced Practitioner in Oncology
|February 18, 2021
PubMed
Summary
This summary is machine-generated.

Biosimilars are highly similar to existing biologics, with no clinically meaningful differences. Presentations covered their chemical and clinical aspects, development in oncology, and strategies for effective implementation in healthcare settings.

More Related Videos

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.1K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.1K

Related Experiment Videos

Last Updated: Nov 17, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

18.0K
Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.1K
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
08:01

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

5.1K

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Biosimilars represent a significant advancement in biologic therapies.
  • Understanding their development and clinical application is crucial for healthcare providers.

Purpose of the Study:

  • To review the chemical and clinical characteristics of biosimilars.
  • To discuss the development pathways for biosimilars in oncology.
  • To explore strategies for the successful implementation of biosimilars.

Main Methods:

  • Discussions and presentations at JADPRO Live 2019.
  • Review of scientific literature on biosimilar development and application.

Main Results:

  • Key aspects of biosimilar nature and development were elucidated.
  • Oncology biosimilar development was specifically addressed.
  • Practical implementation strategies were shared among experts.

Conclusions:

  • Biosimilars offer comparable therapeutic options to originator biologics.
  • Successful integration of biosimilars requires strategic planning and education.
  • Oncology treatments can benefit from the expanded availability of biosimilars.